Recent interest in gene therapies and the genetic constructs on which they are based is causing a flurry of activity in facility construction and expansion. After they are manufactured doses must be stored, shipped, and stored again as they await dosing in far-flung test sites. The physical integrity of doses in these situations is paramount.
A team from the Austin College of Pharmacy and the University of Pennsylvania recently identified factors affecting viral vector viability during shipping and storage at remote test sites. As expected, the formulation, including buffers, cryoprotectants, and general storage conditions, were critical for maintaining stability.